Alps Advisors Inc Assembly Biosciences, Inc. Transaction History

Alps Advisors Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$3.8 - $4.56 $227,023 - $272,428	-59,743 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$4.33 - $6.63 $3,996 - $6,119	923 Added 1.57%	59,743 $275,000
Q4 2020 Feb 03, 2021	BUY	$4.87 - $17.29 $82,400 - $292,546	16,920 Added 40.38%	58,820 $356,000
Q3 2020 Nov 04, 2020	SELL	$15.08 - $27.04 $41,304 - $74,062	-2,739 Reduced 6.14%	41,900 $689,000
Q2 2020 Aug 05, 2020	SELL	$14.57 - $23.96 $171,372 - $281,817	-11,762 Reduced 20.85%	44,639 $1.04 Million
Q1 2020 May 06, 2020	BUY	$10.27 - $21.23 $36,201 - $74,835	3,525 Added 6.67%	56,401 $836,000
Q4 2019 Feb 07, 2020	BUY	$8.36 - $23.81 $13,543 - $38,572	1,620 Added 3.16%	52,876 $1.08 Million
Q3 2019 Nov 04, 2019	SELL	$9.83 - $14.82 $21,812 - $32,885	-2,219 Reduced 4.15%	51,256 $504,000
Q2 2019 Aug 07, 2019	BUY	$12.9 - $20.8 $689,827 - $1.11 Million	53,475 New	53,475 $721,000
Q4 2018 Feb 04, 2019	SELL	$19.05 - $36.45 $857,840 - $1.64 Million	-45,031 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$34.41 - $44.23 $523,272 - $672,605	15,207 Added 50.99%	45,031 $1.67 Million
Q2 2018 Aug 02, 2018	BUY	$39.21 - $50.29 $1.17 Million - $1.5 Million	29,824 New	29,824 $1.17 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $723M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.